{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:13:17Z","timestamp":1780377197024,"version":"3.54.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although aminoglycosides are recommended for cavitary Mycobacterium avium complex lung disease (MAC-LD), the optimal duration of treatment is unclear. We investigated the association between duration of aminoglycoside treatment and outcomes in cavitary MAC-LD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Among patients diagnosed with macrolide-susceptible cavitary MAC-LD between 2000 and 2013, 101 who received treatment up to August 2017 with a regimen containing aminoglycosides were enrolled at a tertiary referral center in South Korea. Their medical records were retrospectively reviewed. The duration of aminoglycoside treatment was at the discretion of the attending physician.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 75 patients (74.3%) were administered aminoglycosides for \u22653 months (median 164 days), whereas the remaining 26 patients (25.7%) received treatment for &amp;lt;3 months (median 59 days). The overall treatment success rate was 63.4% (64\/101). Patients treated with aminoglycosides for \u22653 months had a significantly higher success rate than those treated for &amp;lt;3 months (69.3% vs 46.2%; P = .035). Multivariate analysis revealed that aminoglycoside treatment for \u22653 months was a significant factor for treatment success (adjusted odds ratio, 3.602; 95% confidence interval, 1.249\u201310.390; P = .018). Recurrence occurred in 8 (22.9%) of 35 patients who were followed up for at least 3 years after the end of treatment; all 8 patients received aminoglycosides for \u22653 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with cavitary MAC-LD treated with aminoglycosides for \u22653 months showed higher treatment success rate than those treated for &amp;lt;3 months. However, treatment for \u22653 months was not associated with the development of recurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciy804","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T19:11:44Z","timestamp":1536865904000},"page":"1870-1876","source":"Crossref","is-referenced-by-count":23,"title":["Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease"],"prefix":"10.1093","volume":"68","author":[{"given":"Ock-Hwa","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Soo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkyu","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younsuck","family":"Koh","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Sung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Woo","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Mok","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Do","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Seung","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Man","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Min","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Won","family":"Huh","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Bum","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Wook","family":"Jo","sequence":"additional","affiliation":[{"name":"Division of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,15]]},"reference":[{"key":"2020071700312358200_CIT0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"2020071700312358200_CIT0002","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4046\/trd.2013.75.5.199","article-title":"Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea","volume":"75","author":"Koh","year":"2013","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2020071700312358200_CIT0003","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3346\/jkms.2016.31.5.649","article-title":"Diagnosis and treatment of nontuberculous mycobacterial lung disease","volume":"31","author":"Kwon","year":"2016","journal-title":"J Korean Med Sci"},{"key":"2020071700312358200_CIT0004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071700312358200_CIT0005","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"2020071700312358200_CIT0006","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1513\/AnnalsATS.201303-062OC","article-title":"Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans","volume":"10","author":"Lee","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"2020071700312358200_CIT0007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2016.03.006","article-title":"Update on pulmonary disease due to non-tuberculous mycobacteria","volume":"45","author":"Stout","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2020071700312358200_CIT0008","doi-asserted-by":"crossref","first-page":"1600537","DOI":"10.1183\/13993003.00537-2016","article-title":"Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course","volume":"49","author":"Hwang","year":"2017","journal-title":"Eur Respir J"},{"key":"2020071700312358200_CIT0009","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201107-1203OC","article-title":"Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease","volume":"185","author":"Hayashi","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071700312358200_CIT0010","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020071700312358200_CIT0011","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"key":"2020071700312358200_CIT0012","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0045-2017","article-title":"Mycobacterium avium complex disease","volume":"5","author":"Daley","year":"2017","journal-title":"Microbiol Spectrum"},{"key":"2020071700312358200_CIT0013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4046\/trd.2015.78.3.168","article-title":"Medical management of drug-resistant tuberculosis","volume":"78","author":"Jeon","year":"2015","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2020071700312358200_CIT0014","doi-asserted-by":"crossref","first-page":"336","DOI":"10.4046\/trd.2017.0049","article-title":"WHO treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in South Korea","volume":"80","author":"Jeon","year":"2017","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2020071700312358200_CIT0015","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"2020071700312358200_CIT0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/cid\/ciu209","article-title":"Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death","volume":"59","author":"Vel\u00e1squez","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020071700312358200_CIT0017","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071700312358200_CIT0018","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071700312358200_CIT0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tim.2008.09.008","article-title":"The rpoB gene as a tool for clinical microbiologists","volume":"17","author":"Ad\u00e9kambi","year":"2009","journal-title":"Trends Microbiol"},{"key":"2020071700312358200_CIT0020","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/JCM.38.8.2966-2971.2000","article-title":"Species identification of mycobacteria by PCR-restriction fragment length polymorphism of the rpoB gene","volume":"38","author":"Lee","year":"2000","journal-title":"J Clin Microbiol"},{"key":"2020071700312358200_CIT0021","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00491-18","article-title":"In vitro minimal inhibitory concentrations of rifampin and ethambutol, and treatment outcome in Mycobacterium avium complex lung disease","author":"Kwon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071700312358200_CIT0022","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020071700312358200_CIT0023","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/resp.12676","article-title":"Safety of IV amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease","volume":"21","author":"Ellender","year":"2016","journal-title":"Respirology"},{"key":"2020071700312358200_CIT0024","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"2020071700312358200_CIT0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071700312358200_CIT0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/rccm.201311-2106PP","article-title":"Tuberculosis, pulmonary cavitation, and matrix metalloproteinases","volume":"190","author":"Ong","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071700312358200_CIT0027","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"2020071700312358200_CIT0028","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201802-0321OC","article-title":"Development of macrolide resistance and reinfection in refractory Mycobacterium avium complex lung disease","author":"Jhun","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2020071700312358200_CIT0029","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/Azalide therapy for nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"2020071700312358200_CIT0030","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/AAC.04577-14","article-title":"Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071700312358200_CIT0031","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/thoraxjnl-2012-201756","article-title":"Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes","volume":"68","author":"Jim\u00e9nez-Corona","year":"2013","journal-title":"Thorax"},{"key":"2020071700312358200_CIT0032","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00408-017-9978-4","article-title":"Prevalence and impact of diabetes mellitus among patients with active pulmonary tuberculosis in South Korea","volume":"195","author":"Lee","year":"2017","journal-title":"Lung"},{"key":"2020071700312358200_CIT0033","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000348374","article-title":"Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis","volume":"86","author":"Kang","year":"2013","journal-title":"Respiration"},{"key":"2020071700312358200_CIT0034","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1054\/tuld.1998.0167","article-title":"Hypodense alveolar macrophages in patients with diabetes mellitus and active pulmonary tuberculosis","volume":"79","author":"Wang","year":"1999","journal-title":"Tuber Lung Dis"},{"key":"2020071700312358200_CIT0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/590565","article-title":"Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells","volume":"47","author":"Restrepo","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020071700312358200_CIT0036","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/thoraxjnl-2015-207686","article-title":"The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study","volume":"72","author":"Yoon","year":"2017","journal-title":"Thorax"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/11\/1870\/28653480\/ciy804.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/11\/1870\/28653480\/ciy804.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T14:23:16Z","timestamp":1594995796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/11\/1870\/5098431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,9,15]]},"published-print":{"date-parts":[[2019,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy804","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2018,9,15]]}}}